GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Levetiracetam

Read renal action and limits

Keppra / Levetiracetam / Roweepra

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (5)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
Keppra - product and source limitations

Use the labeled table for the other clearance bands. The XR and injection products have separate source records.

Before applying: Apply only to the stated formulation, indication and renal population.

Roweepra - product and source limitations

Use the renal table for the exact oral product. Confirm the tablet strength and dosing interval.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Keppra - product and source limitations; Roweepra - product and source limitations

Rxlist source

Keppra - selected RX renal passage

Product / population
Levetiracetam (Keppra), adult oral immediate-release
Renal measure
Use the renal measure explicitly present in the RX passage.
Source revision
Mirror revision not established in the reviewed passage.
Retrieved
2026-11-07 (not the revision date)

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

This mirror and the underlying product label share a source family.

RX List: selected renal passage

The mirror calls for renal adjustment and a postdialysis supplemental dose.

Source revision: Mirror revision not established in the reviewed passage. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/keppra-drug/

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Keppra - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 36, posted Jan 29, 2026

Renal measure: CrCl normalized to 1.73 m2, mL/min/1.73 m2

Read this dated source finding
Official

Roweepra - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 5, posted May 26, 2025

Renal measure: CrCl normalized to 1.73 m2, mL/min/1.73 m2

Read this dated source finding
Rxlist

Keppra - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
Rxlist

Roweepra - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

GlobalRPh RX List

Keppra - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Levetiracetam (Keppra), adult oral immediate-release

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Keppra - product and source limitations

Use the labeled table for the other clearance bands. The XR and injection products have separate source records.

How to use this: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Source scope / renal recommendation differences

Roweepra - product and source limitations

Use the renal table for the exact oral product. Confirm the tablet strength and dosing interval.

How to use this: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Historical GlobalRPh table transcription. Verify the exact current product label and whether its creatinine-clearance table is indexed to body surface area before applying it.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/levetiracetam/

Indications and formulation

The source describes KEPPRA adjunctive treatment for partial-onset seizures from age 4 years, myoclonic seizures in juvenile myoclonic epilepsy from age 12 years, and primary generalized tonic-clonic seizures from age 6 years. These recommendations describe immediate-release tablets/oral solution, not extended-release products. Tablets are swallowed whole; treatment may be taken with or without food.

GRPH-levetiracetam-01 · Source section: Indications and formulationRenal section finder

Partial-onset seizures

Adults and adolescents age 16 years or older: start 500 mg twice daily. Increase the total daily dose by 1,000 mg every 2 weeks to 3,000 mg/day. Trials demonstrated efficacy at 1,000, 2,000 and 3,000 mg/day, divided twice daily, without a consistent incremental benefit at higher doses. Doses above 3,000 mg/day were used in open-label treatment for 6 months or longer, but the source reports no evidence of additional benefit.

Children age 4 to under 16 years: start 10 mg/kg twice daily (20 mg/kg/day); increase by 20 mg/kg/day every 2 weeks to 30 mg/kg twice daily (60 mg/kg/day). Reduce if not tolerated. The mean daily dose in the referenced trial was 52 mg/kg/day.

Children weighing 20 kg or less should receive oral solution; those above 20 kg may receive tablets or solution. The source's tablet dosing table gives these twice-daily doses for total daily targets of 20, 40 and 60 mg/kg/day respectively:

  • Weight 20.1-40 kg: 250, 500 and 750 mg twice daily (500, 1,000 and 1,500 mg/day).
  • Weight over 40 kg: 500, 1,000 and 1,500 mg twice daily (1,000, 2,000 and 3,000 mg/day).

Oral solution volume per day (mL) = prescribed daily dose (mg/kg/day) x body weight (kg) / 100 mg/mL. Use a calibrated measuring device, not a household spoon.

GRPH-levetiracetam-02 · Source section: Partial-onset seizuresRenal section finder

Myoclonic and primary generalized tonic-clonic seizures

Myoclonic seizures, age 12 years or older: start 500 mg twice daily; increase by 1,000 mg/day every 2 weeks to 3,000 mg/day. Lower doses were not studied for effectiveness in this indication.

Primary generalized tonic-clonic seizures, age 16 years or older: the same 500 mg twice-daily start and 1,000 mg/day increases every 2 weeks to 3,000 mg/day; effectiveness at lower doses has not been adequately studied.

Primary generalized tonic-clonic seizures, age 6 to under 16: start 20 mg/kg/day divided twice daily; increase by 20 mg/kg/day every 2 weeks to 60 mg/kg/day. Effectiveness below 60 mg/kg/day was not adequately studied. Use solution for patients at or below 20 kg; swallow tablets whole.

GRPH-levetiracetam-03 · Source section: Myoclonic and primary generalized tonic-clonic seizuresRenal section finder

Renal Dosing

The source lists adult creatinine-clearance bands in mL/min:

  • Above 80: 500-1,500 mg every 12 hours.
  • 50-80: 500-1,000 mg every 12 hours.
  • 30-50: 250-750 mg every 12 hours.
  • Below 30: 250-500 mg every 12 hours.
GRPH-levetiracetam-04 · Source section: Renal DosingRenal section finder

Hemodialysis

500-1,000 mg every 24 hours with a supplemental 250-500 mg dose after dialysis.

GRPH-levetiracetam-05 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Keppra - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Levetiracetam (Keppra), adult oral immediate-release

Renal method: CrCl normalized to 1.73 m2, mL/min/1.73 m2
Source date: DailyMed SPL version 36, posted Jan 29, 2026
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.5 Dosage Adjustments in Adult Patients with Renal Impairment / 8.6 Renal Impairment

Adult immediate-release oral dosing uses CrCl adjusted to 1.73 m2. The dialysis row gives 500-1,000 mg every 24 hours and an additional 250-500 mg after dialysis. Use the labeled table for the other clearance bands. The XR and injection products have separate source records.

RDM74-keppra-official-1 · Source locator: Renal guidance: 2.5 Dosage Adjustments in Adult Patients with Renal Impairment / 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ca9df05-a506-4ec8-a4fe-320f1219ab21
Retrieved
2026-11-07
Renal-function method
CrCl normalized to 1.73 m2, mL/min/1.73 m2
Source date/version
DailyMed SPL version 36, posted Jan 29, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
9595303425ca4f3975180a49f888c96c56e77acef583ad87347d0aca7ccdbc71
Official

Roweepra - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Levetiracetam (Roweepra), oral tablet

Renal method: CrCl normalized to 1.73 m2, mL/min/1.73 m2
Source date: DailyMed SPL version 5, posted May 26, 2025
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.5 Dosage Adjustments in Adult Patients with Renal Impairment / 8.6 Renal Impairment

Use body-surface-area-adjusted CrCl to select the adult oral levetiracetam dose. Hemodialysis requires a supplemental dose after the session. Use the renal table for the exact oral product. Confirm the tablet strength and dosing interval.

RDM74-roweepra-official-1 · Source locator: Renal guidance: 2.5 Dosage Adjustments in Adult Patients with Renal Impairment / 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e662bf5b-c81c-4bcd-ba2e-552df95ca6f9
Retrieved
2026-11-07
Renal-function method
CrCl normalized to 1.73 m2, mL/min/1.73 m2
Source date/version
DailyMed SPL version 5, posted May 26, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
9eb2463d30e7c9dfaead629d5f2b46ed12206308d84a6b013f9048add5830952
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Keppra - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Levetiracetam (Keppra), adult oral immediate-release

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror calls for renal adjustment and a postdialysis supplemental dose.

RDM74-keppra-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/keppra-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
595dccb1df472200d3cb8cce378e576c6adffef9c3cf1fd9bf337ef40d1f829c
Rxlist

Roweepra - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Levetiracetam (Roweepra), oral tablet

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

Use body-surface-area-adjusted CrCl to select the adult oral levetiracetam dose. Hemodialysis requires a supplemental dose after the session.

RDM74-roweepra-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/roweepra-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
16f1085bb390731be96ea379a1a2005dbd335ce3c591c566b2655ed42b95e062

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/levetiracetam/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
9039db991063ca0579d41ea0e941bc63cdf88a40f229784fccd646c39ed20375
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top